What is the value basis for the Biocryst (BCRX) director share grant?

The 631-share grant to Jon P. Stonehouse was valued at $8.91 per share. According to the filing footnote, these shares replaced 50% of his quarterly Board Member cash retainer of $11,250, converting part of that fee into stock.

Biocryst (BCRX) director takes share grant instead of cash fee

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Stonehouse Jon P reported acquisition or exercise transactions in this Form 4 filing.

BIOCRYST PHARMACEUTICALS INC director Jon P. Stonehouse reported receiving 631 shares of Common Stock on May 29, 2026. These shares were issued in lieu of 50% of his quarterly Board member cash retainer of $11,250 at a price of $8.91 per share.

After this stock-based retainer, Stonehouse directly holds 1,324,481 shares of Common Stock. The filing also lists 40,000 shares held in the Samuel Stonehouse Irrevocable Trust and 40,000 shares in the Caroline Stonehouse Irrevocable Trust, reported as indirect ownership through his wife as co‑trustee.

Insider Trade Summary

3 transactions reported

Mixed 3 txns

Insider Stonehouse Jon P

Role null

Type	Security	Shares	Price	Value
Grant/Award	Common Stock	631	$8.91	$6K
holding	Common Stock	--	--	--
holding	Common Stock	--	--	--

Holdings After Transaction: Common Stock — 1,324,481 shares (Direct, null); Common Stock — 40,000 shares (Indirect, By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust)

Footnotes (1)

[object Object]

Key Figures

Shares granted: 631 shares Grant price: $8.91 per share Cash retainer reference: $11,250 +3 more

6 metrics

Shares granted 631 shares Common Stock grant on May 29, 2026

Grant price $8.91 per share Value used for stock retainer in lieu of cash

Cash retainer reference $11,250 Quarterly Board Member cash retainer, 50% taken in stock

Direct holdings after grant 1,324,481 shares Common Stock directly held by Jon P. Stonehouse

Samuel Trust holdings 40,000 shares Indirect ownership via Samuel Stonehouse Irrevocable Trust

Caroline Trust holdings 40,000 shares Indirect ownership via Caroline Stonehouse Irrevocable Trust

Key Terms

Form 4, Grant, award, or other acquisition, quarterly cash Board Member retainer, indirect ownership, +1 more

5 terms

Form 4 regulatory

"INSIDER FILING DATA (Form 4):"

Form 4 is a official document that company insiders, such as executives or major shareholders, file with regulators whenever they buy or sell company shares. It provides transparency about how those with inside knowledge are trading, helping investors see if insiders are confident in the company's prospects or may be selling for personal reasons. This information can influence investor decisions by revealing insiders' perspectives on the company's value.

Grant, award, or other acquisition financial

"transaction_code_description: "Grant, award, or other acquisition""

quarterly cash Board Member retainer financial

"in lieu of 50% of the quarterly cash Board Member retainer of $11,250"

indirect ownership financial

"ownership_type: "indirect", ownership_code: "I""

Common Stock financial

"security_title: "Common Stock""

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Form 4 Insider Transactions: What Each Field Means →

06/02/2026 - 04:14 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Stonehouse Jon P

(Last)

(First)

(Middle)

4505 EMPEROR BLVD.

SUITE 200

(Street)

DURHAM

NORTH CAROLINA

27703

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
BIOCRYST PHARMACEUTICALS INC [ BCRX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/29/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/29/2026		A		631⁽¹⁾	A	$8.91	1,324,481	D
Common Stock								40,000	I	By wife as co-trustee of the Caroline Stonehouse Irrevocable Trust
Common Stock								40,000	I	By wife as co-trustee of the Samuel Stonehouse Irrevocable Trust

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. Shares of Common Stock issued to the reporting person in lieu of 50% of the quarterly cash Board Member retainer of $11,250.

	/s/ Alane P. Barnes, by power of attorney	06/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did Biocryst (BCRX) director Jon Stonehouse report in this Form 4?

Jon P. Stonehouse reported receiving 631 shares of Biocryst Common Stock. The shares were issued as stock compensation in place of half of his quarterly Board cash retainer of $11,250, at a price of $8.91 per share.

How many Biocryst (BCRX) shares does Jon Stonehouse hold after this transaction?

After this grant, Jon P. Stonehouse directly holds 1,324,481 Biocryst Common shares. The filing also reports 40,000 shares in each of two irrevocable trusts as indirect holdings through his wife acting as co‑trustee.

Was the Biocryst (BCRX) Form 4 transaction a market purchase or sale?

The Form 4 reports a grant or award acquisition, not a market trade. Shares were issued to Jon P. Stonehouse as compensation in lieu of a portion of his quarterly Board cash retainer, at a stated value of $8.91 per share.

What indirect Biocryst (BCRX) holdings are reported for Jon Stonehouse?

The Form 4 lists 40,000 Biocryst shares in the Samuel Stonehouse Irrevocable Trust and 40,000 in the Caroline Stonehouse Irrevocable Trust. These are reported as indirect ownership, held by his wife as co‑trustee of each trust.